Gone but Not Forgotten: Toward an Integrated Strategy for the Left Atrial Appendage in Atrial Fibrillation Authors: Robert N. D'Angelo, Natalia C. Berry Published: 2026 The left atrial appendage (LAA) is an electrical trigger and dominant source of thromboembolism in atrial fibrillation (AF). LAA electrical isolation (LAAEI) can benefit patients with persistent AF, although study results are heterogeneous. 1 , 2 The BELIEF (Effect of Empirical Left Atrial Appendage Isolation on Long‐term Procedure Outcome in Patients With Persistent or Longstanding Persistent Atrial Fibrillation Undergoing Catheter Ablation) trial showed significantly lower AF recurrence after LAAEI, which was reinforced in subsequent registries and meta‐analyses. 3 , 4 , 5 Stroke after LAAEI remains a significant concern due to electromechanical dissociation, leading to recommendations for LAA occlusion even with appropriate anticoagulation. 3 , 6 , 7 Simultaneously, the role of left atrial appendage closure (LAAC) for stroke reduction continues to expand and generate controversy. The OPTION (Comparison of Anticoagulation With Left Atrial Appendage Closure After Atrial Fibrillation Ablation) trial provided support for LAAC as an alternative to anticoagulation after AF ablation, and CHAMPION‐AF (WATCHMAN FLX Versus NOAC for Embolic ProtectION in the Management of Patients With Non‐Valvular Atrial Fibrillation) recently demonstrated noninferiority between LAAC and novel oral anticoagulants (NOACs) for anticoagulation‐eligible patients. 8 , 9 Yet, CLOSURE‐AF (Left Atrial Appendage CLOSURE in Patients with Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy) found LAAC failed to meet a noninferiority outcome against best medical care in an older, higher‐risk population. 10 Differences in outcomes may be partly driven by periprocedural bleeding and incomplete LAAC, leading to increased thromboembolic risk. A 5‐year follow‐up from PROTECT‐AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation)/PREVAIL (Prospective Randomized Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) showed increased thromboembolic risk with small peri‐device leaks (PDLs), and a recent meta‐analysis supported these findings with computed tomography (CT)‐detected PDLs. 10 , 11 In this context, it is critically important to understand drivers of PDLs and strategies to improve closure. In this issue of the Journal of the American Heart Association (JAHA), Yao and colleagues 12 ask whether LLAAEI improves LAAC success. The investigators identified 686 patients with persistent AF after concomitant catheter ablation and LAAC, using propensity‐score matching to compare 469 patients (363 without LAAEI and 106 with LAAEI). LAAEI was associated with lower rates of PDLs (34.9% versus 49.6%; adjusted odds ratio, 0.69). The protective effect of LAAEI was most pronounced for mild leaks (8.5% versus 21.2%; P=0.003), with no difference for moderate or severe PDLs. Larger LAA orifice diameter predicted PDLs, with LAAEI as the sole protective factor. The benefit was more pronounced for the dual‐seal LACbes® device (disc‐lobe configuration) than for the single‐seal Watchman. The PDL rate in this study (46.3%) seems surprisingly high compared with recent trial data, but the discrepancy likely reflects differences in imaging modality and device design. CHAMPION‐AF reported effective closure (defined as residual leak ≤3 mm) in 98.6% of patients with the Watchman FLX device, predominantly assessed by transesophageal echocardiography (TEE). 8 TEE substantially underestimates PDLs compared with cardiac CT. The SWISS‐APERO (Comparison of Amulet Versus Watchman/FLX Device in Patients Undergoing Left Atrial Appendage Closure) trial directly compared CT and TEE in the same patients and found CT‐detected PDLs were 50% at 45 days with Amulet and Watchman FLX devices compared with TEE‐detected PDLs of 14% to 28%. 13 The PINNACLE FLX (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the Watchman FLX LAA Closure Technology) registry reported 90% freedom from any PDLs at 1 year by TEE; however, CT studies show patency rates in the 40% to 50% range. 14 Consequently, data from Yao et al are consistent with rates of PDLs from CT‐based trials. LAAEI likely improves device endothelization by facilitating disc‐ostium apposition and reducing probability of device shifting due to contractility. These findings are echoed by Mohanty et al, who found lower rates of PDL when patients underwent LAAEI and subsequent Watchman implantation. 15 This effect may be more pronounced for patients with disc‐and‐lobe devices such as the Amulet and LACbes® compared with single‐seal devices such as the Watchman FLX. In the Amulet IDE (AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial) trial, TEE‐detected PDLs ≥3 mm were 10% with Amulet versus 25% with Watchman at 45 days. 16 There is a mechanistic basis for LAAEI preferentially benefitting dual‐seal LACbes® over the single‐seal Watchman. Reduced motion of the LAA may improve disc‐ostium apposition, thereby facilitating improved closure. This mechanism would reduce small PDLs, but would be unlikely to address large leaks due to undersizing, malpositioning, or unfavorable anatomy. This study also adds to our understanding of the thromboembolic management after LAAEI. The BELIEF trial established LAAEI as a rhythm‐control adjunct in longstanding persistent AF, 1 but LAA thrombus was documented in nearly 20% of patients without LAAC. 7 , 17 LAAEI must be coupled with LAAC to reduce thromboembolic risk, but Yao et al suggest the relationship is also reciprocal; LAAEI may also improve the seal quality of LAAC. As ‘one‐stop' approaches to rhythm and thromboembolic risk become increasingly common, it is critical to define strategies to optimize device seal and resultant thromboembolic risk. This study has important limitations. The end point is imaging‐based, but fewer PDLs on CT may not result in fewer strokes; clinically meaningful end points must be included in future studies. Furthermore, the design is single‐center and observational, durable electrical isolation was not confirmed, and there was no longer‐term imaging follow‐up after 3 months. The LACbes® platform is not universally available, and these findings may not be generalizable to other classes of devices. Additionally, LAAEI using now widely adopted pulse‐field ablation was not performed. Nonetheless, this study frames LAAEI and LAAC in an integrated strategy for the management of persistent AF with synergistic effects. Randomized trials linking appendage physiology, device seal, and both short‐ and longer‐term clinical outcomes are essential next steps. We congratulate Yao and colleagues on this important study, which advances our understanding of the relationship between electrical isolation and mechanical closure of the LAA. This work benefits patients by moving us closer to a truly integrated approach, one in which rhythm control and stroke prevention are pursued in concert. Disclosures None.